0000000000148641

AUTHOR

Livio Pagano

showing 7 related works from this author

Zygomycosis in Italy: A survey of FIMUA-ECMM (Federazione Italiana di Micopatologia Umana ed Animale and European Confederation of Medical Mycology)

2009

Abstract The aims of the study were to analyze the clinical and epidemiological characteristics and treatments for patients who developed zygomycosis enrolled in Italy during the European Confederation of Medical Mycology of medical mycology survey. This prospective multicenter study was performed between 2004 and 2007 at 49 italian Departments. 60 cases of zygomycosis were enrolled: the median age was 59.5 years (range 1-87), with a prevalence of males (70%). The majority of cases were immunocompromised patients (42 cases, 70%), mainly hematological malignancies (37). Among non-immunocompromised (18 cases, 30%), the main category was represented by patients with penetrating trauma (7/18, 3…

AdultMalemedicine.medical_specialtyAdolescentEpidemiologyAntifungal drugImmunocompromised HostPharmacotherapyZygomycosisDrug Resistance FungalAmphotericin BInternal medicineEpidemiologymedicineHumansPharmacology (medical)ChildMycosisAgedPharmacologyImmunocompromised hostAged 80 and overbusiness.industryMortality rateMucormycosisInfantEpidemiology; Immunocompromised host; ZygomycosisMiddle Agedmedicine.diseaseSurgeryInfectious DiseasesOncologyItalyChild PreschoolFemaleZygomycosisbusinessmedicine.drug
researchProduct

Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations

2016

Invasive fungal infections (IFIs) are an important cause of morbidity and mortality in immunocompromised patients. Patients with hematological malignancies undergoing conventional chemotherapy, autologous or allogeneic hematopoietic stem cell transplantation are considered at high risk, and Aspergillus spp. represents the most frequently isolated micro-organisms. In the last years, attention has also been focused on other rare molds (e.g., Zygomycetes, Fusarium spp.) responsible for devastating clinical manifestations. The extensive use of antifungal prophylaxis has reduced the infections from yeasts (e.g., candidemia) even though they are still associated with high mortality rates. This pa…

Riskmedicine.medical_specialtySettore MED/06 - Oncologia Medicamedicine.medical_treatmentHematopoietic stem cell transplantationNeutropeniaSettore MED/17 - MALATTIE INFETTIVEHematopoietic stem cell transplantation; Leukemia; Molds; Risk factors; Yeast; Antineoplastic Combined Chemotherapy Protocols; Disease Susceptibility; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Invasive Fungal Infections; Risk; Hematology; OncologyHematopoietic stem cell transplantation; Leukemia; Molds; Risk factors; Yeast; Hematology; OncologyMolds03 medical and health sciences0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansIn patientAspergillusHematologyLeukemiabiologyIncidence (epidemiology)IncidenceHematopoietic Stem Cell TransplantationHematologyhematopoietic stem cell transplantation; Leukemia; Molds; Risk factors; Yeastmedicine.diseasebiology.organism_classificationYeastSettore MED/15 - MALATTIE DEL SANGUELeukemiaOncologyRisk factorsMold030220 oncology & carcinogenesisHematologic NeoplasmsRisk stratificationImmunologyhematopoietic stem cell transplantationRisk factorDisease SusceptibilityInvasive Fungal Infections030215 immunology
researchProduct

T/NK “Nasal Type” Lymphomas: An Italian Cooperative Retrospective Survey.

2004

Abstract T/NK “nasal type” lymphoma is a neoplasm that shows a peculiar geographical distribution. In fact most of the reported cases come from Far Eastern countries such as Hong Kong, and Central America, particularly from Mexico; this kind of lymphoma occurrs rarely in western countries. Between 1997 and 2004, 19 new cases of T/NK nasal type lymphoma were diagnosed in 7 Italian Hematology Division. Patients characteristics were as follows: all caucasian; 14 men and 5 women; median age 53 years (range 20–80). The presentation at the onset was in the nasal cavity or adjacent structures in 15 cases, who presented symptoms like nasal obstruction, dysphagia, orbital edema; in 2 cases, skin les…

Nasal cavitymedicine.medical_specialtyChemotherapyHematologymedicine.diagnostic_testCyclophosphamidebusiness.industrymedicine.medical_treatmentImmunologyCell BiologyHematologymedicine.diseaseBiochemistryLymphomaSurgerymedicine.anatomical_structureInternal medicineBiopsymedicineStage (cooking)medicine.symptombusinessBone painmedicine.drugBlood
researchProduct

Systemic mastocytosis. A GIMEMA multicenter survey

2006

Abstract To evaluate clinical and biological features, treatments and outcome of patients(pts) with Systemic Mastocytosis(SM). A retrospective study (1995–2006) about pts with SM admitted in 14 Italian hematology divisions in tertiary cares or university hospitals. 30 cases of SM were collected(median age 62 y.o.; M/F 14/16) and classified according to the WHO criteria: Mast Cell Leukemia in 14 pts, Aggressive SM in 12 and Indolent in 3; the remaining one had SM with associated clonal non-mast cell-lineage hematologic disease. Skin was the principal extramedullary organ involved (19 pts) followed by spleen(15), liver(13), and cardiovascular system(12). Molecular biology studies were perform…

medicine.medical_specialtyHematologybusiness.industrymedicine.medical_treatmentImmunologyAlpha interferonRetrospective cohort studyImatinibCell BiologyHematologyHematopoietic stem cell transplantationmedicine.diseaseMast cell leukemiaBiochemistryGastroenterologySurgeryHematologic diseaseInternal medicinemedicineSystemic mastocytosisbusinessmedicine.drug
researchProduct

Hematopoietic stem-cell transplantation for advanced systemic mastocytosis

2014

Purpose Advanced systemic mastocytosis (SM), a fatal hematopoietic malignancy characterized by drug resistance, has no standard therapy. The effectiveness of allogeneic hematopoietic stem-cell transplantation (alloHCT) in SM remains unknown. Patients and Methods In a global effort to define the value of HCT in SM, 57 patients with the following subtypes of SM were evaluated: SM associated with clonal hematologic non–mast cell disorders (SM-AHNMD; n = 38), mast cell leukemia (MCL; n = 12), and aggressive SM (ASM; n = 7). Median age of patients was 46 years (range, 11 to 67 years). Donors were HLA-identical (n = 34), unrelated (n = 17), umbilical cord blood (n = 2), HLA-haploidentical (n = 1)…

AdultMaleCancer Researchmedicine.medical_specialtyTransplantation ConditioningAdolescentmedicine.medical_treatmentMedizinDrug resistanceHematopoietic stem cell transplantationMastocytosis SystemicInternal medicinemedicineHumansTransplantation HomologousSystemic mastocytosisChildSurvival rateAgedRetrospective StudiesmastocytosisHematologybusiness.industryRemission InductionHematopoietic Stem Cell TransplantationORIGINAL REPORTSMiddle Agedmedicine.diseaseMast cell leukemia3. Good healthSurvival RateTransplantationSettore MED/15 - MALATTIE DEL SANGUEHaematopoiesisTreatment OutcomeOncologyImmunologyCancer researchFemalebusinesstransplantation
researchProduct

Polymorphisms within the TNFSF4 and mapkapk2 loci influence the risk of developing invasive aspergillosis: A two-stage case control study in the cont…

2020

Here, we assessed whether 36 single nucleotide polymorphisms (SNPs) within the TNFSF4 and MAPKAPK2 loci influence the risk of developing invasive aspergillosis (IA). We conducted a twostage case control study including 911 high-risk patients diagnosed with hematological malignancies that were ascertained through the aspBIOmics consortium. The meta-analysis of the discovery and replication populations revealed that carriers of the TNFSF4rs7526628T/T genotype had a significantly increased risk of developing IA (p = 0.00022). We also found that carriers of the TNFSF4rs7526628T allele showed decreased serum levels of TNFSF14 protein (p = 0.0027), and that their macrophages had a decreased fungi…

Microbiology (medical)Thymic stromal lymphopoietinCiências Médicas::Ciências da Saúde:Ciências da Saúde [Ciências Médicas]lnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4]Context (language use)Single-nucleotide polymorphismPlant ScienceCD38BiologyMonocytes03 medical and health sciencesAll institutes and research themes of the Radboud University Medical Center0302 clinical medicineGenotypeB cells; MAPKAPK2; TNFSF14; TNFSF4; TSLP; genetic susceptibility; invasive aspergillosis; monocytes; serum biomarkersB cells; Genetic susceptibility; Invasive aspergillosis; MAPKAPK2; Monocytes; Serum biomarkers; TNFSF14; TNFSF4; TSLPGenetic predispositionGenetic susceptibilityddc:610Allelelcsh:QH301-705.5Ecology Evolution Behavior and Systematics030304 developmental biology0303 health sciencesB cellsTNFSF14Science & TechnologyTNFSF4Case-control studyMAPKAPK2Serum biomarkers<i>TNFSF4</i>3. Good healthSettore MED/15 - MALATTIE DEL SANGUE<i>MAPKAPK2</i>lcsh:Biology (General)TSLPImmunologyInvasive aspergillosis030215 immunology
researchProduct

Caspofungin for the treatment of candidaemia in patients with haematological malignancies

2010

AbstractThis study was prospectively conducted in 11 haematology divisions over a 2-year period to evaluate the efficacy of caspofungin in 24 neutropenic patients with haematological malignancies (HM) and candidaemia. These patients had received chemotherapy for HM and were neutropenic (PNN < 0.5 × 109/L) for a median of 12 days (2–41) before candidaemia. The patients received caspofungin for a median duration of 12 days (range 6–26), obtaining a favourable overall response of 58%. At 30 days, 11 patients had died (46%); candidaemia was responsible for mortality in six patients (25%). These results suggest that treatment of candidaemia with caspofungin in neutropenic HM was efficacious, as …

AdultMaleMicrobiology (medical)medicine.medical_specialtyAntifungal AgentsNeutropeniaDrug-Related Side Effects and Adverse ReactionsCandidaemia; Caspofungin; Leukaemiamedicine.medical_treatmentAntineoplastic AgentsNeutropeniaEchinocandinsLipopeptidesYoung Adultchemistry.chemical_compoundPharmacotherapyCandidaemiaCaspofunginInternal medicinemedicineHumansLeukaemiaProspective StudiescaspofunginProspective cohort studyMycosisFungemiaAgedChemotherapyHematologybusiness.industryCandidiasisGeneral MedicineMiddle Agedmedicine.diseaseSurgeryTreatment OutcomeInfectious DiseaseschemistryHematologic NeoplasmsleukaemiaFemaleCaspofunginbusinessFungemia
researchProduct